Drugmaker Richter Gedeon Rt announced on Friday it has signed a license and collaboration agreement with Japan's Mitsubishi Pharma Corporation on the development and sale of its atypical antipsychotic RGH-188 in Japan and other Asian markets.
On successful completion of the development, Mitsubishi will have exclusive manufacturing and sales rights in Japan and other Asian countries. “Japan constitutes a traditionally important market for Richter and the company has joined forces with various Japanese firms in the past in the framework of research and other agreements,” the announcement said.
The compound has entered Phase I trials in Japan. Richter noted that, as announced earlier, it already has a collaboration agreement for the development and sale of the same drug with Forest Laboratories Ireland, a unit of US-based Forest Laboratories.